Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Maria Giovanna Cavazzini"'
Autor:
Stefania Gori, Alessandro Inno, Elena Fiorio, Jennifer Foglietta, Antonella Ferro, Marcella Gulisano, Graziella Pinotti, Marta Gubiotti, Maria Giovanna Cavazzini, Monica Turazza, Simona Duranti, Valeria De Simone, Laura Iezzi, Giancarlo Bisagni, Simon Spazzapan, Luigi Cavanna, Chiara Saggia, Emilio Bria, Elisabetta Cretella, Patrizia Vici, Daniele Santini, Alessandra Fabi, Ornella Garrone, Antonio Frassoldati, Laura Amaducci, Silvana Saracchini, Lucia Evangelisti, Sandro Barni, Teresa Gamucci, Lucia Mentuccia, Lucio Laudadio, Alessandra Zoboli, Fabiana Marchetti, Giuseppe Bogina, Gianluigi Lunardi, Luca Boni
Publikováno v:
PLoS ONE, Vol 10, Iss 9, p e0139650 (2015)
Externí odkaz:
https://doaj.org/article/a660a6bec34845daa0ea4fbaedf756d5
Autor:
Stefania Gori, Alessandro Inno, Elena Fiorio, Jennifer Foglietta, Antonella Ferro, Marcella Gulisano, Graziella Pinotti, Marta Gubiotti, Maria Giovanna Cavazzini, Monica Turazza, Simona Duranti, Valeria De Simone, Laura Iezzi, Giancarlo Bisagni, Simon Spazzapan, Luigi Cavanna, Chiara Saggia, Emilio Bria, Elisabetta Cretella, Patrizia Vici, Daniele Santini, Alessandra Fabi, Ornella Garrone, Antonio Frassoldati, Laura Amaducci, Silvana Saracchini, Lucia Evangelisti, Sandro Barni, Teresa Gamucci, Lucia Mentuccia, Lucio Laudadio, Alessandra Zoboli, Fabiana Marchetti, Giuseppe Bogina, Gianluigi Lunardi, Luca Boni
Publikováno v:
PLoS ONE, Vol 10, Iss 9, p e0136731 (2015)
The management of pT1a-b pN0 HER2-positive breast cancer is controversial and no data about the efficacy of trastuzumab in this setting are available from randomized clinical trials. The aims of this retrospective study were to assess how patients ar
Externí odkaz:
https://doaj.org/article/4f836660fd2b420fa85aa8402669e2b7
Autor:
Elena Collovà, Anna Moretti, Livio Blasi, Maria Giovanna Cavazzini, Antonio Bernardo, Claudia Bareggi, Marta Bonotto, Ornella Garrone, Luca Porcu, N. La Verde, Sandro Barni, T Prochilo, Antonella Brunello, Graziella Pinotti
Publikováno v:
Cancer Research. 78:P1-14
BACKGROUND - Metastatic breast cancer (MBC) is a life-threatening disease. It is important to provide data about real-life MBC patients (pts) to understand the current prognostic factors. The aim of the present observational study, named COSMO (Check
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::027b8b37c3b7487e8843481ef90ba713
https://doi.org/10.1158/1538-7445.sabcs17-p1-14-04
https://doi.org/10.1158/1538-7445.sabcs17-p1-14-04
Autor:
Jennifer Foglietta, Laura Iezzi, Ornella Garrone, Daniele Santini, Elisabetta Cretella, M. Turazza, Valeria De Simone, Maria Giovanna Cavazzini, Giancarlo Bisagni, Luigi Cavanna, Patrizia Vici, Silvana Saracchini, Emilio Bria, Elena Fiorio, Luca Boni, Marcella Gulisano, Chiara Saggia, Simon Spazzapan, Lucia Mentuccia, Stefania Gori, Simona Duranti, Marta Gubbiotti, Antonella Ferro, Sandro Barni, Alessandro Inno, Lucia Evangelisti, Francesca Coati, Alessandra Fabi, Gianluigi Lunardi, Lucio Laudadio, Ilaria Marcon
Publikováno v:
Cancer Research. 75:P5-18
Background. The management of small (≤ 1 cm), node-negative, HER2+ve BC is controversial, since data from randomized clinical trials specifically addressing the benefit of adjuvant systemic treatment with or without Trastuzumab in this setting are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fedabe5855188119b9dec92a1bc738eb
https://doi.org/10.1158/1538-7445.sabcs14-p5-18-05
https://doi.org/10.1158/1538-7445.sabcs14-p5-18-05
Autor:
Sandro Pignata, Giovanni Scambia, Dionyssios Katsaros, Ciro Gallo, Eric Pujade Lauraine, DE PLACIDO, SABINO, Alessandra Bologna, Beatrice Weber, Francesco Raspagliesi, Pierluigi Benedetti Panici, Gennaro Cormio, Roberto Sorio, Maria Giovanna Cavazzini, Gabriella Ferrandina, Enrico Breda, Viviana Murgia, Cosimo Sacco, Saverio Cinieri, Vanda Salutari, Caterina Ricci, Carmela Pisano, Stefano Greggi, Rossella Lauria, Domenica Lorusso, Claudia Marchetti, Luigi Selvaggi, Simona Signoriello, Maria Carmela Piccirillo, Massimo Di Maio, Francesco Perrone
BACKGROUND: Carboplatin plus paclitaxel administered every 3 weeks is standard first-line chemotherapy for patients with advanced ovarian cancer. A weekly paclitaxel schedule combined with carboplatin every 3 weeks prolonged progression-free survival
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______3730::db6402cc67be4dd380fa1d86e5986927
http://hdl.handle.net/11588/569157
http://hdl.handle.net/11588/569157
Autor:
Marta Gubiotti, L. Amaducci, Emilio Bria, Ornella Garrone, Giuseppe Bogina, Gianluigi Lunardi, Giancarlo Bisagni, Antonio Frassoldati, Valeria De Simone, Chiara Saggia, Lucia Mentuccia, Patrizia Vici, F. Marchetti, Alessandra Fabi, Simon Spazzapan, Antonella Ferro, Luigi Cavanna, Jennifer Foglietta, Laura Iezzi, Silvana Saracchini, Lucia Evangelisti, Maria Giovanna Cavazzini, Sandro Barni, Elena Fiorio, Luca Boni, M. Turazza, Lucio Laudadio, Simona Duranti, Teresa Gamucci, Elisabetta Cretella, Alessandro Inno, Alessandra Zoboli, Daniele Santini, Graziella Pinotti, Marcella Gulisano, Stefania Gori
Publikováno v:
PLoS ONE
PLoS ONE, Vol 10, Iss 9, p e0136731 (2015)
PLoS ONE, Vol 10, Iss 9, p e0136731 (2015)
The management of pT1a-b pN0 HER2-positive breast cancer is controversial and no data about the efficacy of trastuzumab in this setting are available from randomized clinical trials. The aims of this retrospective study were to assess how patients ar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97208816b369cd5919bfeba6f9b98682
http://europepmc.org/articles/PMC4560419
http://europepmc.org/articles/PMC4560419